|Security||FRAK / Market Vectors Unconventional Oil & Gas ETF (92189F668)|
|Institutional Value||$ 40,998,000 USD|
Institutional Stock Ownership and Shareholders()
Market Vectors Unconventional Oil & Gas ETF (NYSE:FRAK) has 27 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,764,096 shares.
Largest shareholders include
Janney Capital Management LLC, Wells Fargo & Company/mn, Bank Of America Corp /de/, Morgan Stanley, Susquehanna International Group, Llp, Citadel Advisors Llc, Citadel Advisors Llc, Janney Montgomery Scott LLC, Private Capital Management Inc, and Royal Bank Of Canada.
Market Vectors Unconventional Oil & Gas ETF (NYSE:FRAK) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/frak"><img src="https://images.fintel.io/us-frak-so.png" alt="FRAK / Market Vectors Unconventional Oil & Gas ETF Institutional Ownership"><a>
|NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO||600||600||0.00||9||9||0.00|
|ADVANTAGE INVESTMENT MANAGEMENT, LLC||66||66||0.00||1||1||0.00|
|First Allied Advisory Services, Inc.||200||0||-100.00||3||0||-100.00|
|PNC FINANCIAL SERVICES GROUP, INC.||0||135||0||2|
|MML INVESTORS SERVICES, LLC||30,710||0||-100.00||481||0||-100.00|
|CITADEL ADVISORS LLC||52,551||779|
|ROYAL BANK OF CANADA||5,783||14,345||148.05||90||213||136.67|
|Janney Montgomery Scott LLC||48,297||716|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||33,559||79,520||136.96||526||1,179||124.14|
|Parallax Volatility Advisers, L.P.||1||1||0.00||0||0|
|LADENBURG THALMANN FINANCIAL SERVICES INC||265||265||0.00||4||4||0.00|
|Fusion Family Wealth LLC||46||46||0.00||1||1||0.00|
|WELLS FARGO & COMPANY/MN||229,712||241,759||5.24||3,598||3,585||-0.36|
|ENVESTNET ASSET MANAGEMENT INC||5,034||9,389||86.51||79||139||75.95|
|FARMERS & MERCHANTS INVESTMENTS INC||2,900||1,933||-33.34||45||29||-35.56|
|IFP Advisors, Inc||677||499||-26.29||11||7||-36.36|
|JANE STREET GROUP, LLC||0||10,029||0||149|
|Atlantic Trust Group, LLC||215||215||0.00||3||3||0.00|
|BANK OF AMERICA CORP /DE/||45,963||126,818||175.91||720||1,881||161.25|
|Bb&t Investment Services, Inc.||1,530||1,530||0.00||22||24||9.09|
|MetLife Securities, Inc||1,683||31|
|PRIVATE CAPITAL MANAGEMENT INC||14,750||14,750||0.00||206||219||6.31|
|UBS Group AG||4,200||3,340||-20.48||66||50||-24.24|
|CITADEL ADVISORS LLC||91,399||52,551||-42.50||1,431||779||-45.56|
|CAPTRUST FINANCIAL ADVISORS||1,073||1,073||0.00||17||15||-11.76|
|CHILTON CAPITAL MANAGEMENT LLC||27,223||0||-100.00||426||0||-100.00|
|MANUFACTURERS LIFE INSURANCE COMPANY, THE||150||150||0.00||2||2||0.00|
|SMITHFIELD TRUST CO||2,200||2,200||0.00||34||33||-2.94|
|Cutler Group LP||100||0||-100.00||1||0||-100.00|
|Janney Capital Management LLC||1,021,936||2,004,013||96.10||16,003||29,720||85.72|
|Parallel Advisors, LLC||160||160||0.00||3||2||-33.33|
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET